| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
SATB2 (EP281), IMMUNOHISTOCHEMISTRY (IHC)
MessageThis test is ordered by pathologists.
Test Code
1694339439
CPT Codes
88342-TC, Primary;88341-TC, if additional IHC
Preferred Specimen
Formalin-fixed, paraffin-embedded (FFPE) tissue block
Methodology
Immunohistochemistry (IHC)
FDA Status
This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by WVUH in a manner consistent with CLIA requirements.
Clinical Significance
SATB2 IHC staining is primarily used to identify carcinomas of colorectal origin in the setting of a tumor of unknown primary.
SATB2 (special AT-rich sequence-binding protein 2) is a transcription factor, that in combination with CK20, should identify almost all cases of colorectal carcinoma (including poorly differentiated tumors). Upper GI and pancreatic ductal adenocarcinomas are usually negative for SATB2. Ovarian, lung & adenocarcinomas from other sites are only rarely positive.
Other potential uses of SATB2 include: Neuroendocrine neoplasms/carcinomas of the left colon and rectum (SATB2 is usually negative in other neuroendocrine neoplasms of the GI tract, pancreas, and lung). It has also been shown to be a sensitive marker for tumors of
osteoblastic differentiation.
SATB2 (special AT-rich sequence-binding protein 2) is a transcription factor, that in combination with CK20, should identify almost all cases of colorectal carcinoma (including poorly differentiated tumors). Upper GI and pancreatic ductal adenocarcinomas are usually negative for SATB2. Ovarian, lung & adenocarcinomas from other sites are only rarely positive.
Other potential uses of SATB2 include: Neuroendocrine neoplasms/carcinomas of the left colon and rectum (SATB2 is usually negative in other neuroendocrine neoplasms of the GI tract, pancreas, and lung). It has also been shown to be a sensitive marker for tumors of
osteoblastic differentiation.
Performing Laboratory
West Virginia University Hospitals, Inc.
